Hoofddorp, the Netherlands, 18 March 2020. IGEA Pharma (SIX: IGPH) today announced an explosion in the demand for dry aerosol devices in Italy as a result of the COVID-19 outbreak so severely affecting this country.
IGEA operates in air and surfaces sanitization with aerosol technology-based devices following the understandings on the acquisition of privately held Medical Jet. Vincenzo Moccia, CEO of IGEA: “The proven action of our aerosol solutions together with Rely+On Virkon® in reducing a broad spectrum of viruses and bacteria is highly appreciated. We remain fully committed to contribute in solving the problems of contamination of the air and the surfaces in the environments with high infections and life-threatening risk”.
The demand for aerosol solutions in Italy increased by 20 times compared to historic demand. As a result, IGEA and Medial Jet are enhancing the production capacities.
IGEA Pharma focuses on health-tech and med-tech products and devices. Health-tech products are exclusively preventative. IGEA commercializes an Alzheimer’s prevention set (which includes ’Alz1’, an at-home lab test kit to measure non-bound copper in the blood and ‘Alz1 Tab’, a natural dietary supplement designed to reduce blood heavy metals content) and expects to launch a diabetes type II prevention set in 2020. Non-ceruloplasmin bound copper is an expected Alzheimer’s and diabetes type II associated biomarker. Determining and regulating non-bound copper can contribute to reduce the risk of Alzheimer’s and diabetes type II. Med-tech products focuses on selected solutions and specialities. IGEA operates in air and inanimate environmental surface sanitization with aerosol technology-based devices and expects to start commercializing polymeric based infusion and transfusion solutions during 2020.
IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered in Hoofddorp, the Netherlands. Find out more at igeapharma.nl/
Vincenzo Moccia, CEO
Tel +31 23 568 94 94/ +39 340 583 09 33
Patrick Pozzorini, CFO
Tel +31 23 568 94 94/ +41 79 314 41 43
IGEA Pharma N.V.
Siriusdreef 17, 2123 WT Hoofddorp, the Netherlands
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in IGEA.
The information contained in this press release has been carefully prepared. However, IGEA bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. IGEA does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This publication may contain specific forward-looking statements and assessments or intentions concerning IGEA and its business. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of IGEA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes no responsibility to update forward-looking statements or to adapt them to future events or developments, except as may be required by law.